Weiss Asset Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Weiss Asset Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$50.3M	Buy	2,581,813 +873,485	+51%	+$15.8M	0.53%	40
2026 Q1	$31.8M	Buy	1,708,328 +1,375,367	+413%	+$22.8M	0.54%	33
2025 Q4	$4.39M	Buy	+332,961	New	+$3.93M	0.06%	210
2022 Q2	–	Sell	-177,510	Closed	-$1.97M	–	746
2022 Q1	$1.97M	Buy	177,510 +162,510	+1,083%	+$1.62M	0.04%	437
2021 Q4	$148K	Buy	+15,000	New	+$149K	﹤0.01%	626

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Weiss Asset Management's MLTX Position: Q2 2026 in Review

Weiss Asset Management increased its MoonLake Immunotherapeutics (MLTX) stake by 51% in Q2 2026, buying an estimated $15.8M and bringing the position to 2,581,813 shares worth $50.3M. The position accounts for 0.53% of the portfolio, ranked #40.

Weiss Asset Management first reported a position in MLTX in Q4 2021 and has held it in 5 quarters since. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Weiss Asset Management held 2,581,813 shares of MoonLake Immunotherapeutics worth $50.3M as of Q2 2026.
Weiss Asset Management bought 873,485 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $15.8M.
MoonLake Immunotherapeutics made up 0.53% of Weiss Asset Management's portfolio in Q2 2026, its #40 holding.
Weiss Asset Management first reported a position in MoonLake Immunotherapeutics in Q4 2021 and has held it in 5 quarters since.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Weiss Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.